Therefore, novel ASOs could be designed to target the 3′-UTR of STAT6, which could in theory suppress the expression levels of both wild type STAT6 and all known NAB2–STAT6 fusion transcripts, especially if a SFT-tumor-specific ASO delivery method is developed. Here, STAT6 is linked to neoplasm.